GH
Guardant Health, Inc.
Stock
$177.80+3.05 (+1.75%)Close Oct 2, 2026
Income statement
| Line | Last 12 months | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.2B | $982M | $739M | $564M | $450M | $374M | $287M | $214M | $91M | $50M | $25M |
| Cost of revenue | $414M | $349M | $290M | $227M | — | — | — | — | — | — | — |
| Gross profit | $769M | $633M | $449M | $337M | — | — | — | — | — | — | — |
| R&D | $376M | $364M | $348M | $367M | $374M | $263M | $150M | $86M | $51M | $26M | $11M |
| SG&A | $864M | $706M | $545M | $451M | $464M | $399M | $299M | $140M | $90M | $69M | $36M |
| Other operating expenses | — | — | — | $83M | — | — | — | — | — | — | — |
| Operating income | −$470M | −$437M | −$444M | −$565M | −$544M | −$411M | −$255M | −$82M | −$93M | −$77M | −$44M |
| Non-operating income | $16M | $20M | $8.5M | $86M | −$109M | $27M | $9.0M | $13M | $8.7M | −$6.6M | −$2.3M |
| Pretax income | −$454M | −$418M | −$435M | −$479M | −$653M | −$384M | −$246M | −$70M | −$84M | −$83M | −$46M |
| Taxes | −$1.0M | −$1.3M | $1.3M | $685K | $1.1M | $300K | $379K | $5.9M | $838K | $7K | $6K |
| Net income | −$453M | −$416M | −$436M | −$479M | −$655M | −$385M | −$246M | −$76M | −$85M | −$83M | −$46M |
| Diluted EPS | −$3.49 | −$3.32 | −$3.56 | −$4.28 | −$6.41 | −$4.00 | −$2.60 | −$0.84 | −$2.80 | −$7.07 | −$3.53 |
| Diluted shares | — | 125.4M | 122.7M | 112.0M | 102.2M | 101.3M | 97.5M | 90.6M | 30.4M | 12.6M | 13.1M |
| Revenue growth | — | +32.9% | +31.0% | +25.5% | +20.3% | +30.3% | +33.8% | +136.5% | +81.9% | +97.4% | — |
| Gross margin | 65.0% | 64.5% | 60.8% | 59.7% | — | — | — | — | — | — | — |
| Operating margin | −39.7% | −44.5% | −60.0% | −100.1% | −121.1% | −110.0% | −88.9% | −38.4% | −102.5% | −153.7% | −173.7% |
| Net margin | −38.3% | −42.4% | −59.0% | −85.0% | −145.6% | −103.0% | −85.9% | −35.3% | −93.8% | −167.0% | −182.7% |